Pediatrix Medical Group (NYSE:MD) reported fourth-quarter results that matched its recently raised internal projections, as the company’s multi-year restructuring begins to yield a more predictable, hospital-centric financial profile.
Merck (NYSE:MRK) released new data today demonstrating that its recently approved monoclonal antibody, Enflonsia (clesrovimab), remains safe and effective for high-risk children entering their second respiratory syncytial virus (RSV) season.
Materialise (NASDAQ:MTLS) reported fourth-quarter financial results that showcased the growing dominance of its healthcare division, helping the company achieve a significant jump in profitability despite a mixed macroeconomic backdrop.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo moved a step closer to expanding the use of their blockbuster cancer therapy, Enhertu, into the curative-intent setting for early-stage breast cancer.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from its Phase 3b TOGETHER-PsO trial, demonstrating that treating psoriasis and obesity simultaneously yields significantly better outcomes than addressing skin disease alone.
Insulet (NASDAQ:PODD), the Acton, Massachusetts-based maker of the Omnipod insulin delivery systems, reported stronger-than-expected fourth-quarter 2025 results.
Bausch + Lomb (NYSE:BLCO) reported fourth-quarter revenue that surpassed Wall Street expectations, showcasing strong top-line momentum even as the global eye health company posted a net loss for the period.
Outlook Therapeutics (NASDAQ:OTLK) posted a net loss attributable to common stockholders of $23.1 million, or $0.38 per basic and diluted share, for the fiscal first quarter ended December 31, 2025.
Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
Medtronic (NYSE:MDT) reported third-quarter fiscal 2026 revenue of $9.017 billion, an increase of 8.7% as reported and 6.0% on an organic basis, surpassing the midpoint of its guidance by 50 basis points and marking the highest enterprise revenue growth in the past 10 quarters.
Harmony Biosciences Holdings (NASDAQ:HRMY) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) to treat cataplexy in pediatric patients aged six years and older.
Pfizer (NYSE:PFE) today reported positive topline results from Cohort 3 of its pivotal Phase 3 BREAKWATER trial, marking a significant milestone in the treatment of one of the most aggressive forms of colorectal cancer.
